Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Histologic subtypes of ovarian carcinoma: an overview.

Soslow RA.

Int J Gynecol Pathol. 2008 Apr;27(2):161-74. doi: 10.1097/PGP.0b013e31815ea812. Review.

PMID:
18317227
2.

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

McCluggage WG.

Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Review.

PMID:
21716157
3.

My approach to and thoughts on the typing of ovarian carcinomas.

McCluggage WG.

J Clin Pathol. 2008 Feb;61(2):152-63. Epub 2007 Aug 17. Review.

PMID:
17704261
4.

Grading of ovarian cancer: a histotype-specific approach.

Malpica A.

Int J Gynecol Pathol. 2008 Apr;27(2):175-81. doi: 10.1097/PGP.0b013e31816085e0. Review.

PMID:
18317226
6.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
7.
8.

Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.

Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, Sienko A, Morris D, Duggan MA, McCluggage WG, Köbel M.

Am J Surg Pathol. 2017 May;41(5):685-695. doi: 10.1097/PAS.0000000000000812.

PMID:
28125452
9.

Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.

Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA.

Am J Surg Pathol. 2016 Mar;40(3):302-12. doi: 10.1097/PAS.0000000000000550.

11.

Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.

Phillips V, Kelly P, McCluggage WG.

Int J Gynecol Pathol. 2009 Mar;28(2):179-86. doi: 10.1097/PGP.0b013e318182c2d2.

PMID:
19188815
12.

Histological classification of ovarian cancer.

Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H.

Med Electron Microsc. 2003 Mar;36(1):9-17. Review.

PMID:
12658347
13.

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D.

PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232.

14.

Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.

Zhao C, Bratthauer GL, Barner R, Vang R.

Am J Surg Pathol. 2007 Sep;31(9):1378-86.

PMID:
17721194
15.
16.

Clinicopathologic analysis of early-stage sporadic ovarian carcinoma.

Leitao MM Jr, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen RN, Dizon DS, Barakat RR, Soslow RA.

Am J Surg Pathol. 2004 Feb;28(2):147-59.

PMID:
15043303
17.
18.

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency.

Hum Pathol. 2008 Aug;39(8):1239-51. doi: 10.1016/j.humpath.2008.01.003. Epub 2008 Jul 7.

PMID:
18602670
19.

Clinical factors and biomarkers in ovarian tumors development.

Vrabie CD, Petrescu A, Waller M, Dina I.

Rom J Morphol Embryol. 2008;49(3):327-38.

20.

Differences in tumor type in low-stage versus high-stage ovarian carcinomas.

Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC.

Int J Gynecol Pathol. 2010 May;29(3):203-11. doi: 10.1097/PGP.0b013e3181c042b6.

PMID:
20407318

Supplemental Content

Support Center